Insider · CIK 0001726277
Justin J. File
Files at LITS (MEI Pharma, Inc.). First filing -, latest -.
In brief
Justin J. File files SEC Form 4 as CEO, CFO and director at LITS (MEI Pharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Justin J. File has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | LITS MEI Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +455,000 | - | - | 635,000 | Feb 12, 2026 |
| Nov 14, 2025 | LITS MEI Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +180,000 | - | - | 180,000 | Nov 20, 2025 |
| Nov 14, 2025 | LITS MEI Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +635,000 | - | - | 635,000 | Nov 18, 2025 |
| Jul 15, 2025 | LITS MEI Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jul 17, 2025 |
Questions about Justin J. File
Answered from the filings on this page, as of the latest one.
Is Justin J. File buying or selling?
Justin J. File has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Justin J. File's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Justin J. File has 0.
Where does Justin J. File file Form 4?
Justin J. File has filed Form 4 at LITS (MEI Pharma, Inc.) as CEO, CFO and Secretary. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.